Predilife S.A.

Paris Stock Exchange ALPRE.PA

Predilife S.A. Gross Profit for the year ending December 31, 2023: USD 334.60 K

Predilife S.A. Gross Profit is USD 334.60 K for the year ending December 31, 2023, a 27.98% change year over year. Gross profit is the difference between revenue and the cost of revenue, representing the profit earned from core business operations.

Predilife S.A. Gross Profit for the year ending December 31, 2022 was USD 261.45 K, a 111.74% change year over year.
Predilife S.A. Gross Profit for the year ending December 31, 2021 was USD -2.23 M, a -14.44% change year over year.
Predilife S.A. Gross Profit for the year ending December 31, 2020 was USD -1.95 M, a -52.31% change year over year.
Predilife S.A. Gross Profit for the year ending December 31, 2019 was USD -1.28 M, a -1,862.49% change year over year.

Key data

Date	Gross Profit	Operating Income	EBIT	EBITDA

Paris Stock Exchange: ALPRE.PA

Predilife S.A.

CEO	Mr. Stephane Ragusa
IPO Date	Dec. 21, 2018
Location	France
Headquarters	39, Rue Camille Desmoulins
Employees	18
Sector	Health Care
Industries Pharmaceuticals Biotechnology Medical Instruments

Description

Predilife S.A. develops and sells medical techniques and mathematical models. The company provides prevention and breast check-up tests. Its products include MammoRisk, a test for predicting the development of breast cancer based on the patient's individual risk; and DenSeeMammo, a breast density measurement software, as well as a medical device for the prediction of prostate cancer risk. Predilife S.A. was founded in 2004 and is headquartered in Villejuif, France.

Key trends

Past 5 years